Skip to main content

Iothalamate Pregnancy and Breastfeeding Warnings

Brand names: Conray, Conray-30, Conray-400, Conray-43, Cysto-Conray, Cysto-Conray II

Iothalamate Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed.

US FDA pregnancy category: C

Risk summary: No data are available on the use of this drug in pregnant women to inform a drug-related risk.

Animal studies have failed to reveal evidence of impaired fertility or fetal harm. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Iothalamate Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug.

Excreted into human milk: Yes (unchanged)

Comments:
-The effects in the nursing infant are unknown.
-Use bottle feeding for 24 hours following the administration of this drug.

See references

Does Iothalamate interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

See also

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2015) "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc
  4. (2020) "Product Information. Cysto-Conray II (iothalamate)." Mallinckrodt Medical Inc

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2015) "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer